Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company's products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:UPI
CUSIPN/A
Phone+1-952-4266140
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-31.58%
Return on Equity-87.33%
Return on Assets-60.82%
Miscellaneous
EmployeesN/A
Outstanding Shares22,150,000
Market Cap$27.68 million
Uroplasty (NASDAQ:UPI) Frequently Asked Questions
What is Uroplasty's stock symbol?
Uroplasty trades on the NASDAQ under the ticker symbol "UPI."
How were Uroplasty's earnings last quarter?
Uroplasty, Inc. (NASDAQ:UPI) announced its quarterly earnings results on Thursday, January, 22nd. The medical device company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by $0.02. The medical device company earned $6.67 million during the quarter, compared to analysts' expectations of $6.89 million. Uroplasty had a negative net margin of 31.58% and a negative return on equity of 87.33%. View Uroplasty's Earnings History.
Has Uroplasty been receiving favorable news coverage?
Headlines about UPI stock have been trending somewhat positive on Tuesday, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Uroplasty earned a media and rumor sentiment score of 0.15 on Accern's scale. They also assigned news articles about the medical device company an impact score of 46.88 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for Uroplasty.
How do I buy shares of Uroplasty?
Shares of UPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Uroplasty's stock price today?
One share of UPI stock can currently be purchased for approximately $1.22.
How big of a company is Uroplasty?
Uroplasty has a market capitalization of $27.68 million.
How can I contact Uroplasty?
Uroplasty's mailing address is 5420 Feltl Road, MINNETONKA, MN 55343, United States. The medical device company can be reached via phone at +1-952-4266140.
MarketBeat Community Rating for Uroplasty (NASDAQ UPI)
MarketBeat's community ratings are surveys of what our community members think about Uroplasty and other stocks. Vote "Outperform" if you believe UPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UPI will underperform the S&P 500 over the long term. You may vote once every thirty days.
